Hemorragias cerebrales por anticoagulantes, ¿qué hacemos después?

El tractament antitrombòtic després d’una hemorragia intracerebral secundaria a tractament anticoagulant no està ben definit. Realitzem un estudi restropectiu per analitzar els riscos i beneficis de l’antiagregació vs anticoagulació. Evaluem 39 pacients, es va reiniciar l’anticoagulació en 25 i es va canviar a antiagregants a 14 pacients. Després d’un seguiment promig de 54 +/- 31 mesos, trobem que el tractament anticoagulant sembla augmentar el risc de nous events hemorràgics i la mortalitat, sense significació estadística. Son necessaris estudis prospectius per definir el millor tractament després de patir una hemorràgia cerebral per anticoagulants.

Utilidad del complejo protrombínico en el control de la hemostasia en el trasplante cardiaco. experincia en el hospital la fe en el año 2009.

Molts dels pacients que van a ser sotmesos a trasplantament cardíac porten tractament amb anticoagulants orals, que cal revertir preoperatòriament. En aquest estudi es pretén valorar l'eficàcia del complex protrombínic en la reversió de l’anticoagulació oral, realitzant un estudi descriptiu, observacional i retrospectiu dels pacients trasplantats en 2009 en l'Hospital U. La Fe. Resultats: El tractament amb Complex Protrombínic va ser efectiu per a la reversió de l'efecte dels anticoagulants orals, ja que va disminuir el INR (P=0.006) després de la seua administració, amb l'avantatge de tenir un efecte ràpid i un escàs volum.

Cirugía bucal y anticoagulantes orales: una propuesta de actuación

El tratamiento con anticoagulantes orales, fundamentalmente acenocumarol (Sintrom), es cada vez más frecuente en nuestro país. Se ha revisado la literatura médica y odontológica, sobre las pautas terapéuticas empleadas en cirugía bucal en pacientes anticoagulados por vía oral. Se propone un protocolo de actuación basado en que el mantenimiento del régimen anticoagulante oral y el uso local de antifibrinolíticos (ácido tranexámico al 4,8%) como enjuagues, después de la cirugía bucal, disminuye el riesgo tromboembólico y la posibilidad de complicaciones hemorrágicas es comparable a aquellos pacientes que disminuyen el acenocumarol antes de la cirugía bucal.

Pautas de conducta frente a los pacientes bajo tratamiento anticoagulante en la clínica dental.

Nuestro trabajo pretende dar unas ideas básicas para el manejo de pacientes sometidos a tratamiento anticoagulante dando a conocer las posibles pautas a seguir respecto a su medicación: mantener intacta la terapia anticoagulante, modificar la terapia anticoagulante o realizar tratamiento combinado de heparina con anticoagulantes orales. La decisión deberá tomarse conjuntamente con el hematólogo responsable del paciente valorando cada caso según la morbilidad intrínseca de la intervención, el riesgo de tromboembolismo en función de la patología de base que presente el paciente y el grado de coagulación determinado mediante estudios de laboratorio (tiempo de protrombina e índice de trombotest).

Acute coronary syndromes

Mehta et al. do not show any significant difference between early and delayed intervention in patients with acute coronary syndrome. In their study, 9.9% of patients in the...

Acute coronary syndromes

Mehta et al. do not show any significant difference between early and delayed intervention in patients with acute coronary syndrome. In their study, 9.9% of patients in the...

Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial

Influenza vaccines are recommended for administration by the intramuscular route. However, many physicians use the subcutaneous route for patients receiving an oral anticoagulant because this route is thought to induce fewer hemorrhagic side effects. Our aim is to assess the safety of intramuscular administration of influenza vaccine in patients on oral anticoagulation therapy. Methods: Design: Randomised, controlled, single blinded, multi-centre clinical trial. Setting: 4 primary care practices in Barcelona, Spain. Participants: 229 patients on oral anticoagulation therapy eligible for influenza vaccine during the 20032004 season. Interventions: intramuscular administration of influença vaccine in the experimental group (129 patients) compared to subcutaneous administration in the control group (100 patients). Primary outcome: change in the circumference of the arm at the site of injection at 24 hours. Secondary outcomes: appearance of local reactions and pain at 24 hours and at 10 days; change in INR (International Normalized Ratio) at 24 hours and at 10 days. Analysis was by intention to treat using the 95% confidence intervals of the proportions or mean differences. Results: Baseline variables in the two groups were similar. No major side effects or major haemorrhage during the follow-up period were reported. No significant differences were observed in the primary outcome between the two groups. The appearance of local adverse reactions was more frequent in the subcutaneous administration group (37,4% vs. 17,4%, 95% confidence interval of the difference 8,2% to 31,8%). Conclusion: This study shows that the intramuscular administration route of influenza vaccine in patients on anticoagulant therapy does not have more side effects than the subcutaneous administration route

Bivalirudin for patients with acute coronary syndromes

Background: Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors. We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients. Methods: We assigned 13,819 patients with acute coronary syndromes to one of three antithrombotic regimens: unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. The primary end points were a composite ischemia end point (death, myocardial infarction, or unplanned revascularization for ischemia), major bleeding, and the net clinical outcome, defined as the combination of composite ischemia or major bleeding. Results: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor, as compared with heparin plus a glycoprotein IIb/IIIa inhibitor, was associated with noninferior 30-day rates of the composite ischemia end point (7.7% and 7.3%, respectively), major bleeding (5.3% and 5.7%), and the net clinical outcome end point (11.8% and 11.7%). Bivalirudin alone, as compared with heparin plus a glycoprotein IIb/IIIa inhibitor, was associated with a noninferior rate of the composite ischemia end point (7.8% and 7.3%, respectively; P = 0.32; relative risk, 1.08; 95% confidence interval [CI], 0.93 to 1.24) and significantly reduced rates of major bleeding (3.0% vs. 5.7%; P<0.001; relative risk, 0.53; 95% CI, 0.43 to 0.65) and the net clinical outcome end point (10.1% vs. 11.7%; P = 0.02; relative risk, 0.86; 95% CI, 0.77 to 0.97). Conclusions: In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin. Bivalirudin alone was associated with similar rates of ischemia and significantly lower rates of bleeding. (ClinicalTrials.gov number, NCT00093158.)

Prehospital ticagrelor in ST-segment elevation myocardial infarction

Background:The direct-acting platelet P2Y receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown. Methods: We conducted an international, multicenter, randomized, double-blind study involving 1862 patients with ongoing STEMI of less than 6 hours' duration, comparing prehospital (in the ambulance) versus in-hospital (in the catheterization laboratory) treatment with ticagrelor. The coprimary end points were the proportion of patients who did not have a 70% or greater resolution of ST-segment elevation before percutaneous coronary intervention (PCI) and the proportion of patients who did not have Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-related artery at initial angiography. Secondary end points included the rates of major adverse cardiovascular events and definite stent thrombosis at 30 days. Results: The median time from randomization to angiography was 48 minutes, and the median time difference between the two treatment strategies was 31 minutes. The two coprimary end points did not differ significantly between the prehospital and in-hospital groups. The absence of ST-segment elevation resolution of 70% or greater after PCI (a secondary end point) was reported for 42.5% and 47.5% of the patients, respectively. The rates of major adverse cardiovascular events did not differ significantly between the two study groups. The rates of definite stent thrombosis were lower in the prehospital group than in the in-hospital group (0% vs. 0.8% in the first 24 hours; 0.2% vs. 1.2% at 30 days). Rates of major bleeding events were low and virtually identical in the two groups, regardless of the bleeding definition used

¿Sepsis en LES?. Anticoagulante lúpico. Cuatro casos clínicos pediátricos

En el lupus eritematoso diseminado no son infrecuentes los trastornos de la coagulación, con hemorragias, que incluso en ocasiones pueden ser la primera manifestación; si además se añade fiebre puede malinterpretarse como un cuadro infeccioso, sabre todo si se acompaña de la presencia de anticoagulante lúpico (inmunoglobulina presente en el l0-25% de los casos, con afinidad por los fosfolípidos cargados negativamente, que impide que el proceso de coagulación in vitro se desarrolle normalmente), ya que se asemejará a una sepsis con coagulopatía. Los cuatro casas reseñados son ejemplos de esta situación. Una minuciosa anamnesis y examen clínico, la correcta interpretación de los exámenes complementarios junto con la sospecha diagnóstica son básicos en la orientación de estos pacientes.

Atividade fisica e sintomas musculo-esqueleticos : explorando relações em população de calouros de medicina

Universidade Estadual de Campinas. Faculdade de Educação Física

Atividade fisica, um paradoxo para a saude : estudo a partir de universitários recem-ingressos ao Curso de Medicina

Universidade Estadual de Campinas . Faculdade de Educação Física

Sintomas psicológicos concomitantes à queixa de vertigem em 846 prontuários de pacientes otoneurológicos do Ambulatório de Otoneurologia da Universidade Federal de São Paulo - Escola Paulista de Medicina

OBJETIVO: Verificar os sintomas psicológicos mais freqüentemente associados à queixa de vertigem de acordo com os registros de prontuários de pacientes otoneurológicos. FORMA DE ESTUDO: Clínico retrospectivo. MÉTODO: Foram quantificados os dados relativos a sexo, idade e sintomas psicológicos, de acordo com os registros de 846 prontuários de triagem de pacientes otoneurológicos com queixa de vertigem, atendidos pelo Setor de Triagem do Ambulatório de Otoneurologia e Otoneuropsicologia da Universidade Federal de São Paulo - Escola Paulista de Medicina, nos períodos de 1999 a 2001. RESULTADOS: A concomitância de sintomas psicológicos à queixa de vertigem foi verificada em 477 (56,38%), de um total de 846 prontuários. Os sintomas psicológicos associados à queixa de vertigem foram a angústia (47,38%), a ansiedade (19,71%), o medo (13,42%) a depressão (12,58%) e os distúrbios de memória (6,92%). CONCLUSÃO: A angústia foi o sintoma psicológico concomitante à queixa de vertigem de maior prevalência (47,38%).

Resultados auditivos com o implante coclear multicanal em pacientes submetidos a cirurgia no Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

A surdez profunda é uma deficiência que afeta a personalidade, o relacionamento e todo o estilo de vida do paciente. Incapacita os indivíduos de escutarem sons ambientes como sirenes e alarmes que constituem alerta em situações da vida diária e não permite a modulação vocal, tornando a voz esteticamente ruim. A prótese auditiva convencional é eficiente no tratamento de grande parte das deficiências auditivas, porém existem pacientes que não conseguem obter discriminação de palavras e sentenças mesmo com uma prótese auditiva potente. O implante coclear é a alternativa atual para estes pacientes. OBJETIVO: Avaliar o resultado auditivo dos pacientes adultos implantados com o implante coclear multicanal pelo Grupo de Implante Coclear da Disciplina de Otorrinolaringologia da Faculdade de medicina da Universidade de São Paulo. FORMA DE ESTUDO: Estudo de série. CASUÍSTICA E MÉTODO: Foram selecionados 61 pacientes com surdez profunda bilateral que utilizam o implante coclear multicanal por pelo menos seis meses e estudados os resultados auditivos através de testes de reconhecimento de palavras e sentenças. RESULTADOS: O PTA médio obtido pelos pacientes foi 38.7 dB NPS. A média em reconhecimento de sentenças em formato aberto foi de 71.3%, vogais em 86.5%, monossílabos em 52.60% e consoante medial em 52.6%. A maioria dos pacientes está apta ao uso do telefone. CONCLUSÃO: A avaliação auditiva obtida seis meses após a primeira programação do implante demonstra que pacientes de língua portuguesa obtêm excelentes resultados em testes de reconhecimento de palavras e sentenças em apresentação aberta, readquirindo uma audição útil.